AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

RecruitingPhase 2Ages any - anyAllOno Pharmaceutical Co., Ltd.
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Subjects completed Study YKP3089C035 by SK Life Science. Exclusion Criteria: * Subjects that have previously discontinued for any reason from the Core study (YKP3089C035). * Any significant changes to the medical history of the subject that in the opinion of the investigator, could affect the safety of the subject.
๐Ÿ’Š

What it tests

  • Cenobamate
๐Ÿ“

Where

29 sites
Ehime University Hospital
Ehime, Japan
Department of Neurology and Stroke Center, Southern Tohoku Clinic.
Fukushima, Japan
Hiroshima University Hospital
Hiroshima, Japan
NHO Kure Medical Center and Chugoku Cancer Center
Hiroshima, Japan
Asahikawa Medical University Hospital
Hokkaido, Japan
Itami City Hospital
Hyลgo, Japan
JA-Ibaraki Tsuchiura Kyodo General Hospital
Ibaraki, Japan
University of Tsukuba Hospital
Ibaraki, Japan

โ€ฆand 21 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy